Europe Has A Platform For Driving More Flexible Clinical Trials: It's Time To Use It

By Katarina Nedog, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Europe's standing in the global landscape of clinical research is facing a significant downturn. Despite an overall surge in commercial trials worldwide, the European Economic Area has witnessed a concerning decline in its share over the last decade. This shift translates to tens of thousands fewer patients gaining access to crucial trials within Europe. Recent data paint a clear picture of a research system grappling with slowness and fragmentation. However, a collective commitment exists to revitalize Europe's potential as a prime location for clinical studies. Turning this commitment into tangible results is now paramount. Discover the challenges and the collaborative efforts underway to reverse this trend.